{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T18:59:13Z","timestamp":1712343553633},"reference-count":83,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.critrevonc.2014.06.002","type":"journal-article","created":{"date-parts":[[2014,7,20]],"date-time":"2014-07-20T09:16:52Z","timestamp":1405847812000},"page":"268-278","source":"Crossref","is-referenced-by-count":9,"title":["Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria"],"prefix":"10.1016","volume":"92","author":[{"given":"Jean","family":"Klastersky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aspasia","family":"Georgala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2014.06.002_bib0005","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.critrevonc.2010.03.008","article-title":"Febrile neutropenia: a critical review of the initial management","volume":"78","author":"Klastersky","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0015","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdm525","article-title":"Cost of neutropenic complications of chemotherapy","volume":"19","author":"Weycker","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0020","first-page":"92","article-title":"Gram-negative bacteremia","volume":"110","author":"McCabe","year":"1962","journal-title":"Int Arch Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0025","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.ijantimicag.2007.06.012","article-title":"Bacteremia in febrile neutropenia cancer patients","volume":"30S","author":"Klastersky","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0030","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJM197105132841904","article-title":"Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia","volume":"284","author":"Schimpff","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0035","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/jac\/dkp075","article-title":"Why empirical therapy?","volume":"63","author":"Klastersky","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0040","first-page":"174","article-title":"Evaluation of gentamicin with carbenicillin in infections due to gram-negative bacilli","volume":"13","author":"Klastersky","year":"1971","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pa.08.040168.001055","article-title":"The use of combinations of antimicrobial drugs","volume":"8","author":"Jawetz","year":"1968","journal-title":"Annu Rev Pharmacol"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0050","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1128\/AAC.2.6.470","article-title":"Clinical significance of in vitro synergism between antibiotics in gram-negative infections","volume":"2","author":"Klastersky","year":"1972","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0055","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/infdis\/129.2.187","article-title":"Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections","volume":"129","author":"Klastersky","year":"1974","journal-title":"J Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0060","first-page":"96","article-title":"Antibiotic synergism response in gram-negative bacteremia in granulocytopenic cancer patients","volume":"80","author":"De Jongh","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0065","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJM198712313172703","article-title":"The EORTC International Antimicrobial Therapy Cooperative Group: ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia","volume":"317","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0070","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1086\/383046","article-title":"Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia","volume":"39","author":"Tamura","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0075","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ijantimicag.2010.11.029","article-title":"Clinical implications of \u03b2-lactam-aminoglycoside synergism: systematic review of randomized trials","volume":"37","author":"Ronit","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1473-3099(02)00241-4","article-title":"Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenia patients: a meta-analysis","volume":"2","author":"Furno","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0085","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0090","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/annonc\/mdq196","article-title":"Management of febrile neutropenia: ESMO clinical practice guidelines","volume":"21","author":"De Naurois","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0095","first-page":"CD005197","article-title":"Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams","volume":"11","author":"Paul","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0100","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1086\/376637","article-title":"Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin\u2013tazobactam monotherapy","volume":"37","author":"Cometta","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0105","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ijantimicag.2008.06.017","article-title":"Bloodstream infections in cancer patients with febrile neutropenia","volume":"32","author":"Feld","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0110","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenia cancer patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0115","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00520-010-0993-8","volume":"19","author":"Hui","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0120","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00520-007-0334-8","article-title":"Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in cancer (MASCC) risk index: feasibility and safety in routine clinical practice","volume":"16","author":"Innes","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2354.2007.00780.x","article-title":"Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procacitonin, C-reactive protein, serum amyloid A, and interleukins-1\u03b2, -6, -8 and -10","volume":"16","author":"Uys","year":"2007","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0130","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00520-010-0925-7","article-title":"Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?","volume":"19","author":"Paesmans","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0135","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/annonc\/mdn655","article-title":"A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies","volume":"20","author":"Moreau","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0140","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.leukres.2009.08.024","article-title":"The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease","volume":"34","author":"Park","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0145","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00520-010-0928-4","article-title":"Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia","volume":"19","author":"Ahn","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0150","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1056\/NEJM199907293410502","article-title":"Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy","volume":"341","author":"Kern","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0155","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00520-007-0383-z","article-title":"Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge","volume":"16","author":"Sebban","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.bjc.6600993","article-title":"Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomized controlled single centre study","volume":"89","author":"Innes","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0165","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1200\/JCO.2005.03.9909","article-title":"Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications","volume":"24","author":"Klastersky","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc8972","article-title":"Febrile neutropenia in French emergency departments: results of a prospective multicentre survey","volume":"14","author":"Andr\u00e9","year":"2010","journal-title":"Critical Care"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0175","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4161\/cbt.9.8.11270","article-title":"Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48hours","volume":"9","author":"Mato","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0180","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1634\/theoncologist.12-8-1019","article-title":"Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care","volume":"12","author":"Courtney","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00520-001-0312-5","article-title":"Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients","volume":"10","author":"Berghmans","year":"2002","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0190","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-3148.2009.00988.x","article-title":"The value and practicality of granulocyte transfusion: a single oncology centre","volume":"20","author":"Al-Tanbal","year":"2010","journal-title":"Transfus Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0195","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.critrevonc.2009.01.003","article-title":"Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics","volume":"72","author":"Wingard","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0200","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.critrevonc.2014.06.002_bib0205","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1471-2407-11-404","article-title":"Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis","volume":"23","author":"Cooper","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0210","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0215","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0220","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(08)70284-6","article-title":"Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta-analysis","volume":"9","author":"Schlesinger","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0225","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/150.3.372","article-title":"Trimethoprim\u2013sulfamethoxazole in the prevention of infection in neutropenic patients","volume":"150","author":"EORTC International Antimicrobial Therapy Project Group","year":"1984","journal-title":"J Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0230","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1056\/NEJMoa050078","article-title":"Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas","volume":"353","author":"Cullen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0235","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0240","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1128\/AAC.38.4.681","article-title":"Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center","volume":"38","author":"Kern","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0245","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10096-005-1278-x","article-title":"Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia","volume":"24","author":"Kern","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0250","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jac\/dkm514","article-title":"Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution","volume":"61","author":"Cattaneo","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0255","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1086\/432940","article-title":"Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infection: the role of inadequate empirical antimicrobial therapy","volume":"41","author":"Lautenbach","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0260","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1054\/drup.1998.0068","article-title":"Mechanisms of fluoroquinolone resistance","volume":"2","author":"Hooper","year":"1999","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0265","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkl404","article-title":"Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens","volume":"58","author":"Chenia","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0270","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1086\/428052","article-title":"Mechanisms of resistance to quinolones","volume":"41","author":"Jacoby","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0275","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1473-3099(06)70599-0","article-title":"The worldwide emergence of plasmid-mediated quinolone resistance","volume":"6","author":"Robicsek","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0280","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum B-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0285","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1590\/S0100-879X2009000300010","article-title":"Factors associated with bacteremia due to multidrug-resistant gram-negative bacilli in hematopoietic stem cell transplant recipients","volume":"42","author":"Garnica","year":"2009","journal-title":"Braz J Med Res"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0290","unstructured":"NCCN guidelines. Available from: www.nccn.org."},{"issue":"Oct (10)","key":"10.1016\/j.critrevonc.2014.06.002_bib0295","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0300","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1097-2765(00)80402-5","article-title":"Signal transduction by a death signal peptide: uncovering the mechanism of bacterial killing by penicillin","volume":"5","author":"Novak","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0305","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1126\/science.293.5536.1786","article-title":"Humans as the world's greatest evolutionary force","volume":"293","author":"Palumbi","year":"2001","journal-title":"Science"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2014.06.002_bib0310","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1093\/clinids\/24.Supplement_1.S85","article-title":"Antibiotic resistance in streptococcus pneumonia","volume":"24","author":"Tomasz","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0315","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/clinids\/21.5.1107","article-title":"The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms","volume":"21","author":"Jacobson","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0320","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/JCM.32.3.691-696.1994","article-title":"Detection of Klebsiella pneumonia and Escherichia coli strains producing extended-spectrum lactamases","volume":"32","author":"Katsanis","year":"1994","journal-title":"J Clin Microbiol"},{"issue":"11","key":"10.1016\/j.critrevonc.2014.06.002_bib0325","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1128\/AAC.34.11.2200","article-title":"Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lacatms in clinical isolates of Klebsiella pneumonia","volume":"34","author":"Papanicolaou","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0330","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile beta-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0335","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1128\/AAC.35.1.147","article-title":"Transferable imipenem resistance in Pseudomonas aeruginosa","volume":"35","author":"Watanabe","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0340","unstructured":"CRE in Europe \u2013 Current European situation and future plans for control. Available from: www.ecdc.europa.eu."},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0345","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJM200105243442102","article-title":"A nosocomial outbreak of fluoroquinolone-resistant salmonella infection","volume":"344","author":"Olsen","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0350","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1128\/AAC.43.11.2736","article-title":"Emergence and dissemination of quinolone-resistant Escherichia coli in the community","volume":"43","author":"Garau","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0355","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMp0804651","article-title":"Antibiotic-resistant bugs in the 21st century \u2013 a clinical super challenge","volume":"360","author":"Arias","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0360","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMra0904124","article-title":"Hospital-acquired infections due to gram-negative bacteria","volume":"362","author":"Peleg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0370","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1128\/AAC.45.3.781-785.2001","article-title":"In vitro pharmacodynamics properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis","volume":"45","author":"Li","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0375","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/IAI.23.3.660-664.1979","article-title":"Polymyxin B sulfate modification of bacterial endotoxin: effects of the development of endotoxin shock in dogs","volume":"23","author":"From","year":"1979","journal-title":"Infect Immun"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0380","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJMcibr0808335","article-title":"Does the Trojan horse have an Achille's heel?","volume":"360","author":"Dougan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0385","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1517\/13543784.16.11.1831","article-title":"Agents under investigation for the treatment and prevention of neutropenia","volume":"16","author":"Huston","year":"2007","journal-title":"Expert Opin Invest Drug"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.0604320","article-title":"Antimicrobial proteins and peptides: anti-infective molecules of mammalian leukocytes","volume":"76","author":"Levy","year":"2004","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0395","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/infdis\/157.5.869","article-title":"Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America","volume":"157","author":"Marr","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0400","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/513766","article-title":"Society for Healthcare Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals","volume":"25","author":"Shlaes","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"Jan (4)","key":"10.1016\/j.critrevonc.2014.06.002_bib0405","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJM199801223380406","article-title":"A computer-assisted management for antibiotics and other antiinfective agents","volume":"338","author":"Evans","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0410","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0415","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1086\/664762","article-title":"Implementation of a clinical decision support system for antimicrobial stewardship","volume":"33","author":"Hermsen","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.critrevonc.2014.06.002_bib0420","series-title":"ICAAC 2012, San Francisco, California","author":"Fishman","year":"1922"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842814001139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842814001139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T12:21:31Z","timestamp":1598098891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842814001139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1040842814001139"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2014.06.002","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}